Oleg A. Voylenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oleg A. Voylenko has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Maksym V. Pikul
Department of Plastic and Reconstructive Oncourology National Cancer Institute of Ukraine Kyiv Ukraine
9 shared publications - Sofiya L. Semko
National Cancer Institute, Kyiv
8 shared publications - Eduard O. Stakhovsky
Department of Plastic and Reconstructive Oncological Urology, National Cancer Institute, Kyiv, Ukraine
7 shared publications - Iurii Vitruk
National Cancer Institute, Kyiv
7 shared publications - Oleksii A. Kononenko
National Cancer Institute, Kyiv
7 shared publications I. Vitruk
4 shared publications
Latest Publications
- 26 December 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 42 (2) , 31.e9-31.e15
Comparison of aggressiveness in central versus peripheral T1a clear-cell renal cell carcinoma
- 26 December 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 42 (2) , 31.e9-31.e15
Comparison of aggressiveness in central versus peripheral T1a clear-cell renal cell carcinoma
- Open Access
- 24 August 2023
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 4(80),p. 24-33
Modification of fast-track surgery during partial nephrectomy
The present study aimed to assess the efficacy of the multimodal fast-track surgery (FTS) program supplemented with the exclusion of renal thermal ischemia, urinary tract drainage, and postoperative wound management in patients undergoing partial nephrectomy for localized T1 RCC. Methods. A total of 150 patients diagnosed with localized RCC in stage T1 N0 M0 were initially enrolled in this prospective randomized study, with 75 patients assigned to each study group. Patients undergoing perioperative management following the FTS program were randomly assigned to the main study group. The control group comprised patients receiving standard postoperative care. The study specifically involved patients with kidney neoplasms not exceeding 7 cm in the largest diameter based on computed tomography data. Tumor size, localization, and the volume of functioning parenchyma were considered in the assessment. Results. Among the patients included, 24 cases (16%) underwent radical nephrectomy due to technical difficulties arising from tumor spread to the kidney hilum, rendering them ineligible for further analysis. Consequently, the clinical analysis focused on 126 patients. Within the main group, 64 cases (50.8%) of RCC underwent randomization, and the multimodal FTS program was applied during partial nephrectomy. The control group comprised 62 patients (49.2%). The median postoperative bed day in the main group was 1.5 days less compared to the control group, with values of 3.2 [2; 4] days versus 5 [4; 7] days, respectively (p < 0.001). Intraoperative complications occurred in 5 cases (4.0%) involving blood loss exceeding 1 liter (4 cases in the main group and 1 case in the control group). Transfusion of blood components occurred only once when the hemoglobin level dropped below 70 g/l. In the early postoperative period, a total of 9 complications (7.1%) were observed with pyelonephritis lasting more than 3 days diagnosed in 4 cases (3.2%) and wound suppuration in 1 case (0.8%). Despite the absence of drainage in postoperative wounds within the main group, ultrasound examinations revealed small retroperitoneal hematomas (up to 100 ml) requiring drainage in 3% of cases. Conclusions. The multimodal FTS program for patients with localized RCC during partial nephrectomy, coupled with the exclusion of central thermal ischemia of the kidney, avoidance of retroperitoneal space drainage, and early patient activation, demonstrated a significant reduction in postoperative bed while maintaining a comparable level of perioperative complications.
- 24 August 2023
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 4(80),p. 24-33
Open AccessModification of fast-track surgery during partial nephrectomy
The present study aimed to assess the efficacy of the multimodal fast-track surgery (FTS) program supplemented with the exclusion of renal thermal ischemia, urinary tract drainage, and postoperative wound management in patients undergoing partial nephrectomy for localized T1 RCC. Methods. A total of 150 patients diagnosed with localized RCC in stage T1 N0 M0 were initially enrolled in this prospective randomized study, with 75 patients assigned to each study group. Patients undergoing perioperative management following the FTS program were randomly assigned to the main study group. The control group comprised patients receiving standard postoperative care. The study specifically involved patients with kidney neoplasms not exceeding 7 cm in the largest diameter based on computed tomography data. Tumor size, localization, and the volume of functioning parenchyma were considered in the assessment. Results. Among the patients included, 24 cases (16%) underwent radical nephrectomy due to technical difficulties arising from tumor spread to the kidney hilum, rendering them ineligible for further analysis. Consequently, the clinical analysis focused on 126 patients. Within the main group, 64 cases (50.8%) of RCC underwent randomization, and the multimodal FTS program was applied during partial nephrectomy. The control group comprised 62 patients (49.2%). The median postoperative bed day in the main group was 1.5 days less compared to the control group, with values of 3.2 [2; 4] days versus 5 [4; 7] days, respectively (p < 0.001). Intraoperative complications occurred in 5 cases (4.0%) involving blood loss exceeding 1 liter (4 cases in the main group and 1 case in the control group). Transfusion of blood components occurred only once when the hemoglobin level dropped below 70 g/l. In the early postoperative period, a total of 9 complications (7.1%) were observed with pyelonephritis lasting more than 3 days diagnosed in 4 cases (3.2%) and wound suppuration in 1 case (0.8%). Despite the absence of drainage in postoperative wounds within the main group, ultrasound examinations revealed small retroperitoneal hematomas (up to 100 ml) requiring drainage in 3% of cases. Conclusions. The multimodal FTS program for patients with localized RCC during partial nephrectomy, coupled with the exclusion of central thermal ischemia of the kidney, avoidance of retroperitoneal space drainage, and early patient activation, demonstrated a significant reduction in postoperative bed while maintaining a comparable level of perioperative complications.
- 23 July 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (7) , 3131-3137
Advantages of organ-sparing treatment approaches in metastatic kidney cancer
Purpose This study analyzed oncological outcomes of patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with cytoreductive partial nephrectomy or nephrectomy. Methods This prospective non-randomized cohort study included 109 patients with metastatic ccRCC who underwent surgical treatment between 2011 and 2020. Patients were stratified into cytoreductive partial nephrectomy or nephrectomy groups. Survival curves were estimated, and Cox-regression analysis was performed to identify factors affecting potential lethality. Results The groups differed significantly in terms of T stage and International metastatic RCC database consortium (IMDC) risk groups, but not international society of urological pathology (ISUP) grading. The average blood loss volume was higher in the partial nephrectomy group. In contrast, the duration of post-operative stay, complication rate; and 30-day hospital readmission rate were similar between two groups. There was a significant difference in overall survival in favor of the partial nephrectomy group, who had better 7-year survival rates. Standardization based on the clinical complexity of the patients showed that cytoreductive partial nephrectomy was associated with a lower risk of death compared to nephrectomy. Conclusion Partial nephrectomy is a safe method of choice in patients with metastatic ccRCC. Kidney preservation in a metastatic setting can play a role in reducing potential adverse systemic therapy events and in decreasing the risk for concomitant pathology deterioration.
- 23 July 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (7) , 3131-3137
Advantages of organ-sparing treatment approaches in metastatic kidney cancer
Purpose This study analyzed oncological outcomes of patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with cytoreductive partial nephrectomy or nephrectomy. Methods This prospective non-randomized cohort study included 109 patients with metastatic ccRCC who underwent surgical treatment between 2011 and 2020. Patients were stratified into cytoreductive partial nephrectomy or nephrectomy groups. Survival curves were estimated, and Cox-regression analysis was performed to identify factors affecting potential lethality. Results The groups differed significantly in terms of T stage and International metastatic RCC database consortium (IMDC) risk groups, but not international society of urological pathology (ISUP) grading. The average blood loss volume was higher in the partial nephrectomy group. In contrast, the duration of post-operative stay, complication rate; and 30-day hospital readmission rate were similar between two groups. There was a significant difference in overall survival in favor of the partial nephrectomy group, who had better 7-year survival rates. Standardization based on the clinical complexity of the patients showed that cytoreductive partial nephrectomy was associated with a lower risk of death compared to nephrectomy. Conclusion Partial nephrectomy is a safe method of choice in patients with metastatic ccRCC. Kidney preservation in a metastatic setting can play a role in reducing potential adverse systemic therapy events and in decreasing the risk for concomitant pathology deterioration.
- Open Access
- 30 April 2021
- Published by Wiley in Advances in Urology
- Vol. 2021, 1-7
Efficacy of Neoadjuvant Targeted Therapy in Treatment of Patients with Localised Clear-Cell Renal Cell Carcinoma
Aim. This study aimed to evaluate the efficacy of neoadjuvant targeted therapy (TT) in patients with localised clear-cell renal cell carcinoma (RCC). Materials and Methods. A special randomised trial was planned and conducted by the Research Department of Plastic and Reconstructive Oncology in the National Cancer Institute of Ukraine for testing the clinical efficacy of neoadjuvant TT in the treatment of clear-cell localised RCC, and the primary endpoint was tumour response evaluation after TT. The secondary endpoints included evaluation of dependence between the use of neoadjuvant TT and the probability of partial nephrectomy and the correlation between tumour size, stage, remaining functioning parenchyma volume, and response to systemic therapy. Results. Overall, 118 patients met the inclusion criteria and were randomly assigned to receive combined treatment or surgery alone. The percentage of tumour regression ranged from 0% to 60%, and the median was (95% confidence interval) 20.5 ± 14.3 (16.8–24.3%). Most of the patients had a slightly positive response to TT (3%–29% decrease in tumour size); n = 44 (76.9%) cases. Partial response by the Response Evaluation Criteria in Solid Tumours, version 1.1, was observed in 14 (24.1%) patients and reached a maximum of 60% regression. Tumour reduction in the neoadjuvant TT group allowed kidney preservation in 53 (91.4%) patients. In the control group, the number of organ-sparing procedures was significantly lower (n = 20, 33.3%). The statistical difference was relevant (x2 = 42.1; ). Conclusion. The positive results of neoadjuvant TT obtained in our study indicate the clinical validity of combined treatment in patients with localised RCC.
- 30 April 2021
- Published by Wiley in Advances in Urology
- Vol. 2021, 1-7
Open AccessEfficacy of Neoadjuvant Targeted Therapy in Treatment of Patients with Localised Clear-Cell Renal Cell Carcinoma
Aim. This study aimed to evaluate the efficacy of neoadjuvant targeted therapy (TT) in patients with localised clear-cell renal cell carcinoma (RCC). Materials and Methods. A special randomised trial was planned and conducted by the Research Department of Plastic and Reconstructive Oncology in the National Cancer Institute of Ukraine for testing the clinical efficacy of neoadjuvant TT in the treatment of clear-cell localised RCC, and the primary endpoint was tumour response evaluation after TT. The secondary endpoints included evaluation of dependence between the use of neoadjuvant TT and the probability of partial nephrectomy and the correlation between tumour size, stage, remaining functioning parenchyma volume, and response to systemic therapy. Results. Overall, 118 patients met the inclusion criteria and were randomly assigned to receive combined treatment or surgery alone. The percentage of tumour regression ranged from 0% to 60%, and the median was (95% confidence interval) 20.5 ± 14.3 (16.8–24.3%). Most of the patients had a slightly positive response to TT (3%–29% decrease in tumour size); n = 44 (76.9%) cases. Partial response by the Response Evaluation Criteria in Solid Tumours, version 1.1, was observed in 14 (24.1%) patients and reached a maximum of 60% regression. Tumour reduction in the neoadjuvant TT group allowed kidney preservation in 53 (91.4%) patients. In the control group, the number of organ-sparing procedures was significantly lower (n = 20, 33.3%). The statistical difference was relevant (x2 = 42.1; ). Conclusion. The positive results of neoadjuvant TT obtained in our study indicate the clinical validity of combined treatment in patients with localised RCC.
- Open Access
- 1 July 2020
- Published by Elsevier in European Urology Open Science
- Vol. 19, e238
Influence of neoadjuvant targeted therapy on perioperative complication rate
- 1 July 2020
- Published by Elsevier in European Urology Open Science
- Vol. 19, e238
Open AccessInfluence of neoadjuvant targeted therapy on perioperative complication rate
- Open Access
- 26 May 2020
- Published by Liga-Inform, Ltd. in Klinicheskaia khirurgiia
- Vol. 87 (1-2) , 53-59
Impact of neoadjuvant targeted therapy on perioperative complications in patients with localized reno-cellular cancer
Objective. To study the efficacy of neoadjuvant targeted therapy in treatment of localized reno-cellular cancer and to determine its impact on the perioperative complications rate. Materials and methods. There are presented the results of randomized investigation, conducted in 152 patients with localized reno-cellular cancer. Into the main group 75 (49.3%) patients were included, to whom neoadjuvant targeted therapy and operative treatment were conducted, and into the control group - 77 (50.7%) patients, to whom operative treatment was performed only. The groups were randomized in accordance to the main clinical parameters. Efficacy of treatment was estimated in accordance to RECIST 1.1 scale, complications – in accordance to Clavien-Dindo classification. Results. Neoadjuvant targeted therapy did not influence the operation duration: (95 ± 19) min – while conduction of targeted therapy and (108 ± 53) min – without conduction of targeted therapy, and duration of postoperative treatment: (5.6 ± 1.9) and (5.2 ± 2.3) bed-days, accordingly. The intraoperative blood loss volume in renal resection of the patients’ main group in comparison with patients of a control group have constituted (407 ± 224) and (317 ± 210) ml accordingly (p=0.013). Neoadjuvant targeted therapy did not influence the perioperative complications rate, which have occurred in 7 (9.3%) patients of the main and in 8 (10.7%) patients of a control group, and their severity did not exceed 3 degrees in accordance to Clavien-Dindo classification. Conclusion. Neoadjuvant targeted therapy do not increase the operation duration, the perioperative complications rate and postoperative treatment time, but increases the blood loss volume while performance of renal resection (p=0.013).
- 26 May 2020
- Published by Liga-Inform, Ltd. in Klinicheskaia khirurgiia
- Vol. 87 (1-2) , 53-59
Open AccessImpact of neoadjuvant targeted therapy on perioperative complications in patients with localized reno-cellular cancer
Objective. To study the efficacy of neoadjuvant targeted therapy in treatment of localized reno-cellular cancer and to determine its impact on the perioperative complications rate. Materials and methods. There are presented the results of randomized investigation, conducted in 152 patients with localized reno-cellular cancer. Into the main group 75 (49.3%) patients were included, to whom neoadjuvant targeted therapy and operative treatment were conducted, and into the control group - 77 (50.7%) patients, to whom operative treatment was performed only. The groups were randomized in accordance to the main clinical parameters. Efficacy of treatment was estimated in accordance to RECIST 1.1 scale, complications – in accordance to Clavien-Dindo classification. Results. Neoadjuvant targeted therapy did not influence the operation duration: (95 ± 19) min – while conduction of targeted therapy and (108 ± 53) min – without conduction of targeted therapy, and duration of postoperative treatment: (5.6 ± 1.9) and (5.2 ± 2.3) bed-days, accordingly. The intraoperative blood loss volume in renal resection of the patients’ main group in comparison with patients of a control group have constituted (407 ± 224) and (317 ± 210) ml accordingly (p=0.013). Neoadjuvant targeted therapy did not influence the perioperative complications rate, which have occurred in 7 (9.3%) patients of the main and in 8 (10.7%) patients of a control group, and their severity did not exceed 3 degrees in accordance to Clavien-Dindo classification. Conclusion. Neoadjuvant targeted therapy do not increase the operation duration, the perioperative complications rate and postoperative treatment time, but increases the blood loss volume while performance of renal resection (p=0.013).
- Open Access
- 20 December 2019
- Published by Liga-Inform, Ltd. in Klinicheskaia khirurgiia
- Vol. 86 (11-12) , 56-62
Quality of life in patients, suffering localized reno-cellular cancer after operative treatment
Objective. To rise the efficacy of treatment in patients, suffering localized reno-cellular cancer (LRCC), studying quality of life in patients and determination of optimal procedure of operative treatment. Materials and methods. Of 511 patients, suffering LRCC (T1-T2 N0M0), in whom quality of life was estimated in accordance to the SF-36 questionnaire, renal resection was performed in 422 (82.6%), nephrectomy - 89 (17.4%). The observation duration median have constituted 28.9 mo (from 3 to 131 mo). Results. A patient’s cognition of the oncological disease missing have raised the quality of life self-estimation, predominantly in accordance to indices of psychological component of health after nephrectomy and after renal resection. Comparing the quality of life between the patients’ groups, there was obtained a statistically significant advantage of renal resection over nephrectomy in accordance to five indices of quality of life, including: physical functioning - 75 [65; 85] points after nephrectomy and 80 [70; 90] points after renal resection (p < 0.005); general state of health - 65 [57; 72] and 70 [65; 80] (p < 0.001); vital activity - 65 [55; 70] and 70 [60; 75] (p < 0.005); psychological health - 76 [60; 80] and 80 [68; 88] (p < 0.005); the emotionally-role functioning - 66.7 [66.7; 100] and 100 [66,7; 100] (p < 0.05) points, accordingly. Conclusion. Renal resection has a statistically proven advantage over nephrectomy in accordance to patients’ quality of life, determined, basing on data from the SF-36 questionnaire, predominantly due to better psychological self estimation of the patient’s state of health (p < 0.01). Difference between the investigated groups in accordance to indices of pain intensity, social and physical-role functioning was not established.
- 20 December 2019
- Published by Liga-Inform, Ltd. in Klinicheskaia khirurgiia
- Vol. 86 (11-12) , 56-62
Open AccessQuality of life in patients, suffering localized reno-cellular cancer after operative treatment
Objective. To rise the efficacy of treatment in patients, suffering localized reno-cellular cancer (LRCC), studying quality of life in patients and determination of optimal procedure of operative treatment. Materials and methods. Of 511 patients, suffering LRCC (T1-T2 N0M0), in whom quality of life was estimated in accordance to the SF-36 questionnaire, renal resection was performed in 422 (82.6%), nephrectomy - 89 (17.4%). The observation duration median have constituted 28.9 mo (from 3 to 131 mo). Results. A patient’s cognition of the oncological disease missing have raised the quality of life self-estimation, predominantly in accordance to indices of psychological component of health after nephrectomy and after renal resection. Comparing the quality of life between the patients’ groups, there was obtained a statistically significant advantage of renal resection over nephrectomy in accordance to five indices of quality of life, including: physical functioning - 75 [65; 85] points after nephrectomy and 80 [70; 90] points after renal resection (p < 0.005); general state of health - 65 [57; 72] and 70 [65; 80] (p < 0.001); vital activity - 65 [55; 70] and 70 [60; 75] (p < 0.005); psychological health - 76 [60; 80] and 80 [68; 88] (p < 0.005); the emotionally-role functioning - 66.7 [66.7; 100] and 100 [66,7; 100] (p < 0.05) points, accordingly. Conclusion. Renal resection has a statistically proven advantage over nephrectomy in accordance to patients’ quality of life, determined, basing on data from the SF-36 questionnaire, predominantly due to better psychological self estimation of the patient’s state of health (p < 0.01). Difference between the investigated groups in accordance to indices of pain intensity, social and physical-role functioning was not established.
- Open Access
- 28 February 2019
- Published by Liga-Inform, Ltd. in Klinicheskaia khirurgiia
- Vol. 86 (3) , 32-36
Особливості морфологічних змін в оцінці ефективностінеоад’ювантної таргетної терапії у хворих з локалізованимнирково–клітинним раком
Мета. Визначити особливості морфологічних змін під впливом неоад’ювантної таргетної терапії (ТТ), проведеної хворим з локалізованим нирково-клітинним раком (НКР). Матеріали і методи. Вивчено дані 58 пацієнтів з локалізованим НКР, яким проведено два блоки неоад’ювантної ТТ з визначенням об’єктивної відповіді на лікування, подальшим оперативним втручанням та патоморфологічним дослідженням. Результати. Середній показник регресії пухлини (М ± SD) після проведення ТТ становив (20,5 ± 14,3)% (95% довірчий інтервал- ДІ 16 - 24,3). Оцінка регресії пухлини за шкалою RECIST 1.1: стабілізацію відмітили у 44 (75,9%) хворих; часткову регресію- у 14 (24,1%). Повної регресії чи прогресії процесу не спостерігали у жодного хворого. Середній показник регресії за навності 2-го ступеня градації за Фурманом становив (22,6 ± 14,4)% (95% ДІ 18,3 - 26,9); 3-го ступеняг радації за Фурманом - (17,1 ± 11,7)% (95% ДІ 7,3 - 26,9); 4-го ступеня градації за Фурманом - (3,8 ± 2,9)% (95% ДІ 1 - 8,5); оцінка за методом ANOVA: η2=0,13; power=0,72; p < 0,05. Середня частка некрозу пухлини під дією ТТ достовірно вище у хворих з частковою регресією. Кореляційної залежності тяжкості судинних змін та частки життєздатної пухлинної тканини від ступеня регресії НКР не виявлено. Висновки. Під впливом неоад’ювантної ТТ у хворих з локалізованим НКР відбулася регресія пухлини в середньому на (20,5 ± 14,3)%. Низький показник регресії НКР у хворих з 4-м ступенем гістопатологічної градації ядер за Фурманом - (3,8 ± 2,9)%, який свідчить про низьку ефективність ТТ (оцінка за методом ANOVA: η2 = 0,13; power = 0,72; p < 0,05), можна використовувати як прогностичний маркер відповіді.
- 28 February 2019
- Published by Liga-Inform, Ltd. in Klinicheskaia khirurgiia
- Vol. 86 (3) , 32-36
Open AccessОсобливості морфологічних змін в оцінці ефективностінеоад’ювантної таргетної терапії у хворих з локалізованимнирково–клітинним раком
Мета. Визначити особливості морфологічних змін під впливом неоад’ювантної таргетної терапії (ТТ), проведеної хворим з локалізованим нирково-клітинним раком (НКР). Матеріали і методи. Вивчено дані 58 пацієнтів з локалізованим НКР, яким проведено два блоки неоад’ювантної ТТ з визначенням об’єктивної відповіді на лікування, подальшим оперативним втручанням та патоморфологічним дослідженням. Результати. Середній показник регресії пухлини (М ± SD) після проведення ТТ становив (20,5 ± 14,3)% (95% довірчий інтервал- ДІ 16 - 24,3). Оцінка регресії пухлини за шкалою RECIST 1.1: стабілізацію відмітили у 44 (75,9%) хворих; часткову регресію- у 14 (24,1%). Повної регресії чи прогресії процесу не спостерігали у жодного хворого. Середній показник регресії за навності 2-го ступеня градації за Фурманом становив (22,6 ± 14,4)% (95% ДІ 18,3 - 26,9); 3-го ступеняг радації за Фурманом - (17,1 ± 11,7)% (95% ДІ 7,3 - 26,9); 4-го ступеня градації за Фурманом - (3,8 ± 2,9)% (95% ДІ 1 - 8,5); оцінка за методом ANOVA: η2=0,13; power=0,72; p < 0,05. Середня частка некрозу пухлини під дією ТТ достовірно вище у хворих з частковою регресією. Кореляційної залежності тяжкості судинних змін та частки життєздатної пухлинної тканини від ступеня регресії НКР не виявлено. Висновки. Під впливом неоад’ювантної ТТ у хворих з локалізованим НКР відбулася регресія пухлини в середньому на (20,5 ± 14,3)%. Низький показник регресії НКР у хворих з 4-м ступенем гістопатологічної градації ядер за Фурманом - (3,8 ± 2,9)%, який свідчить про низьку ефективність ТТ (оцінка за методом ANOVA: η2 = 0,13; power = 0,72; p < 0,05), можна використовувати як прогностичний маркер відповіді.
- Open Access
- 30 January 2019
- Published by Liga-Inform, Ltd. in Klinicheskaia khirurgiia
- Vol. 85 (1) , 56-60
Визначення оптимальної тривалості проведення неоад’ювантної таргетної терапії хворим з локалізованим нирково-клітинним раком
Мета. Визначити оптимальну тривалість проведення неоад’ювантної таргетної терапії (ТТ) в лікуванні хворих з локалізованим нирково-клітинним раком (НКР). Матеріали і методи. До рандомізованого проспективного дослідження включено 24 пацієнти з локалізованим світлоклітинним НКР (Т1а-2bN0M0), яких розподілено на дві групи: 1-ша група - 12 пацієнтів, яким проведено два блоки неоад’ювантної ТТ (пазопаніб 800 мг щоденно перорально протягом 28 днів); 2-га група - 12 пацієнтів, яким проведено чотири блоки неоад’ювантної ТТ. Результати. Стабілізацію (шкала RECIST 1.1) констатували у 9 (75%) пацієнтів 1-ї групи та у 8 (67%) - 2-ї групи, часткову відповідь - у 3 (25%) та 4 (33%) пацієнтів відповідно (χ2= 0,2; р = 0,65). Медіани показника регресії пухлини в 1-й та 2-й групах були порівнянні: 18 [2; 27] і 17 [2; 34]% відповідно. Значущої різниці між частотою побічних проявів за шкалою CTC AE ступенів 1 - 4, виконання нефректомії, інтра- та післяопераційних ускладнень та тривалістю госпіталізації в порівнюваних групах не виявлено (р > 0,05). Висновки. Оптимальною тривалістю проведення неоад’ювантної ТТ хворим з локалізованим НКР є використання двох блоків. Більша тривалість неоад’ювантної ТТ призводить до збільшення вартості лікування без подальшої регресії НКР, що не впливає на вибір тактики хірургічного втручання.
- 30 January 2019
- Published by Liga-Inform, Ltd. in Klinicheskaia khirurgiia
- Vol. 85 (1) , 56-60
Open AccessВизначення оптимальної тривалості проведення неоад’ювантної таргетної терапії хворим з локалізованим нирково-клітинним раком
Мета. Визначити оптимальну тривалість проведення неоад’ювантної таргетної терапії (ТТ) в лікуванні хворих з локалізованим нирково-клітинним раком (НКР). Матеріали і методи. До рандомізованого проспективного дослідження включено 24 пацієнти з локалізованим світлоклітинним НКР (Т1а-2bN0M0), яких розподілено на дві групи: 1-ша група - 12 пацієнтів, яким проведено два блоки неоад’ювантної ТТ (пазопаніб 800 мг щоденно перорально протягом 28 днів); 2-га група - 12 пацієнтів, яким проведено чотири блоки неоад’ювантної ТТ. Результати. Стабілізацію (шкала RECIST 1.1) констатували у 9 (75%) пацієнтів 1-ї групи та у 8 (67%) - 2-ї групи, часткову відповідь - у 3 (25%) та 4 (33%) пацієнтів відповідно (χ2= 0,2; р = 0,65). Медіани показника регресії пухлини в 1-й та 2-й групах були порівнянні: 18 [2; 27] і 17 [2; 34]% відповідно. Значущої різниці між частотою побічних проявів за шкалою CTC AE ступенів 1 - 4, виконання нефректомії, інтра- та післяопераційних ускладнень та тривалістю госпіталізації в порівнюваних групах не виявлено (р > 0,05). Висновки. Оптимальною тривалістю проведення неоад’ювантної ТТ хворим з локалізованим НКР є використання двох блоків. Більша тривалість неоад’ювантної ТТ призводить до збільшення вартості лікування без подальшої регресії НКР, що не впливає на вибір тактики хірургічного втручання.
- 1 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e861
861 Nephron sparing surgery in patients with intravenous extension of renal cell carcinoma
- 1 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e861
861 Nephron sparing surgery in patients with intravenous extension of renal cell carcinoma